Navigation Links
Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
Date:3/17/2009

Test aiding diagnosis of mental retardation, birth defects, and autism spectrum and developmental disorders now approved for use on patients in New York

MADISON, N.J., March 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its ClariSure(TM) microarray-based comparative genomic hybridization (aCGH) postnatal test is now available for testing on patients in the state of New York. With licensure by the State Department of Health Clinical Laboratory Evaluation Program, Quest Diagnostics operates one of only three laboratories in the U.S. approved to perform aCGH testing on postnatal samples collected on patients in New York. The state has approved the use of the ClariSure aCGH postnatal test as an aid in detecting copy-number chromosomal abnormalities implicated in dozens of medical conditions, including mental retardation, birth defects, and autism spectrum and developmental disorders, which conventional laboratory tests may fail to detect.

"With approval by New York State, our advanced ClariSure test has demonstrated that it fulfills test validation requirements widely regarded as among the most rigorous in the lab industry," said Charles (Buck) Strom, M.D., Ph.D., medical director of the genetic testing center of Quest Diagnostics Nichols Institute, the esoteric testing laboratory and research and development center of Quest Diagnostics. "Since its launch in mid-2007, physicians outside of New York have used our ClariSure test to identify the genetic etiology of congenital anomalies, autism and other disorders for dozens of patients whose conditions had eluded prior diagnostic efforts. We look forward to providing broader access to our ClariSure test, so that more parents have the diagnostic insights they need to provide appropriate schooling and social support to their infants and children."

Scientists at Nichols Institute have validated the ClariSure test's ability to use a single blood specimen to identify chromosomal abnormalities associated with dozens of disorders, including Down, cri du chat, DiGeorge and Williams syndromes. A positive result may be confirmed using a fluorescence in situ hybridization (FISH) methodology.

aCGH technologies compare and contrast a specimen's DNA to the DNA of a healthy individual to identify, at a high resolution, extra or missing genetic material in the specimen. These technologies can detect a proportion of additional abnormalities even in patients who have already had extensive cytogenetic and/or FISH testing. aCGH tests are also more efficient, as multiple tests are required to generate the same amount of information produced from one microarray-based test. Chromosome abnormalities, such as extra copies of chromosomes and other copy number changes, have been implicated in some types of mental retardation, developmental disorder and congenital anomalies, as well as in autism and autism spectrum disorders.

In the U.S., the clinical laboratory testing services are regulated under the federal Clinical Laboratory Clinical Laboratory Improvement Amendments (CLIA). Laboratory-developed tests must fulfill CLIA requirements, including validation studies, before they can be introduced to their markets. New York has the only state licensure program which requires pre-approval of a laboratory's validation procedure prior to testing of patient samples. Under the state program, laboratory-developed tests must be able to demonstrate they perform as intended, according to clinical and analytical validation studies, before they can be used to conduct testing on specimens collected in the state.

Quest Diagnostics Nichols Institute will provide information about the ClariSure postnatal test at its exhibit at the 2009 American College of Medical Genetics (ACMG) conference in Tampa, Florida. The exhibit will be open from March 26 to March 28.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.questdiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business" in Part I, Item 1, "Risk Factors" and "Cautionary Factors that May Affect Future Results" in Part I, Item 1A, "Legal Proceedings" in Part I, Item 3, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 and "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A in the company's 2008 Annual Report on Form 10-K and other items throughout the Form 10-K and Current Reports on Form 8-K.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
5. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
6. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
7. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Colorado Cancer Research Program Will Host Golf Event to Drive the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer
10. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
11. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... New York , May 31, 2016 ... other biomaterials market is progressing at a CAGR of ... This market was valued at US$0.46 bn in 2013. ... it is expected to reach US$0.88 bn by the ... data is derived from the market,s holistic representation in ...
(Date:5/31/2016)... Israel , May 31, 2016 CollPlant ... proprietary plant-based rhCollagen technology for tissue repair products - ... Scientist of Israel,s Ministry of ... million development project for 2016. The Chief Scientist,s grant amount ... authorized grant, which totaled NIS 4.7 million.  ...
(Date:5/30/2016)... PUNE, India , May 30, 2016 ... new market research report "Healthcare Biometrics Market ... Behavioral (Signature, Voice)), Multifactor, Multimodal), Application (Workforce ... Global Forecast to 2021", published by MarketsandMarkets, ... 2,848.3 Million by 2021 from USD 1,182.6 ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop first demonstrated its ... something that contractors should have at their disposal on a daily basis. , ... Director of Contractor Programs. , As a result, Metloop and CertainTeed entered ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... particular advertising campaigns, to monitor the performance of sales and support staff, and ... and revenue. The software allows customers to record, transcribe, route, document, and report ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Effective leaders not ... and the industry as a whole. On June 2, Northbound CEO Mike Neatherton and ... Disorders (WCSAD) and presenting the opening plenary on “Leadership: The Journey to Authenticity” with ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Like jewels in ... clients already know – London is home to Ontario’s leading day spa and one ... visionary Fayez Tamba began with a unique concept to combine spa services with ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... WaterField ... for digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ... waxed canvas or ballistic nylon, the Duo is smartly designed for Dad’s ...
Breaking Medicine News(10 mins):